← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity
HomeStocksPTHSRevenue History
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

PTHS logoPelthos Therapeutics Inc. (PTHS) Revenue History

Annual and quarterly revenue from 2022 to 2024

TTM Revenue
$7.4M
0
YoY Growth
-
Latest Quarter
$7.4M
Q3 2025
QoQ Growth
-

Compound Annual Growth Rate (CAGR)

3-Year-
5-Year-
10-Year-
Highest Annual Revenue$0 (0)
Highest Quarter$7.4M (Q3 2025)
Revenue per Share$12.60
Revenue per Employee$1.9M

Loading revenue history...

PTHS Revenue Growth

1-Year Growth
-
3-Year CAGR
-
5-Year CAGR
-
10-Year CAGR
-
TTM vs Prior Year-
Revenue per Share$12.60
Revenue per Employee$1.9M
Peak Annual Revenue$0 (0)

Download Historical Data

3 records • Includes OHLCV + Technical Indicators (MA50, MA200, RSI)

Free sign in required to download data

PTHS Revenue Analysis (2022–2024)

As of May 7, 2026, Pelthos Therapeutics Inc. (PTHS) generated trailing twelve-month (TTM) revenue of $7.4 million. The most recent quarter (Q3 2025) recorded $7.4 million in revenue.

Looking at the longer-term picture, PTHS's historical revenue data shows various trends over time.

When compared to Healthcare sector peers including COLL (+23.6% YoY), AVDL (+79.9% YoY), and SUPN (+16.3% YoY). Compare PTHS vs COLL →

PTHS Revenue vs Peers

Revenue metrics vs comparable public companies

CompanyTTM RevenueYoY Growth5Y CAGROp. MarginCompare
PTHS logoPTHSCurrent$7M---
COLL logoCOLL$781M+23.6%+20.3%24.0%
AVDL logoAVDL$169M+79.9%+23.4%-25.1%
SUPN logoSUPN$719M+16.3%+6.7%-5.1%
LNTH logoLNTH$1.5B+0.5%+35.3%20.2%
Best in groupLowest in group

PTHS Historical Revenue Data (2022–2024)

Showing 3 of 3 records
Year Revenue YoY % Gross Profit Gross Margin Op. Income Op. Margin
2024$0-$0-$-7,571,449-
2023$0-$0-$-6,862,284-
2022$0-$0-$-2,318,159-

See PTHS's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is PTHS Undervalued?

DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.

View Valuation

Compare PTHS vs DBVT

Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..

Start Comparison

PTHS — Frequently Asked Questions

Quick answers to the most common questions about buying PTHS stock.

Is PTHS's revenue growth accelerating or slowing?

PTHS TTM revenue: $7M. YoY growth: N/A. 5-year CAGR: N/A.

What is PTHS's long-term revenue growth rate?

Pelthos Therapeutics Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.

How is PTHS's revenue distributed by segment?

PTHS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2022-2024 are available for download. Segment mix reveals concentration and diversification trends.

VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.

PTHS Revenue Over Time (2022–2024)